Intravesical therapy - BCG and beyond

H. Barton Grossman, Donald Lamm, Gottfrid Sjodahl, Michael O'donnell, Noah Hahn, Ashish Kamat

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to life threatening disease. Intravesical Bacillus Calmette-Gúerin (BCG), one of the earliest effective immunotherapies for cancer, remains the current standard for treating high-risk non-muscle invasive bladder cancer. Optimal treatment with BCG includes periodic 3 weekly maintenance instillations, often with dose reduction to minimize toxicity. However, despite its efficacy, treatment failure is common. Efforts to provide alternate and potentially more effective therapy for this disease include increased understanding of bladder cancer through molecular profiling, multi-agent intravesical chemotherapy, and novel forms of immunotherapy.

Original languageEnglish (US)
Pages (from-to)73-80
Number of pages8
JournalBladder Cancer
Issue number1
StatePublished - 2019


  • Bcg
  • Bladder cancer
  • Immunotherapy
  • Intravesical chemotherapy
  • Molecular profiling

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Intravesical therapy - BCG and beyond'. Together they form a unique fingerprint.

Cite this